A Phase 2 interventional study of ADX-102 Ophthalmic Drops (0.5%) and ADX-102 Ophthalmic Drops (0.1%) in Conjunctivitis, Allergic, sponsored by Aldeyra Therapeutics, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-09.
Sponsored by Aldeyra Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Conjunctivitis, Allergic with a site in United States — 6 open to participants now, 7 under way, 2 of them phase 3. Conjunctivitis, Allergic · United States.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, this one is the 24th largest by enrollment of the 90 interventional ones that give a count, is one of 2 that started in 2016, is one of 25 in phase 2, and was the 65th registered.
211 studies on the registry are indexed under Conjunctivitis, Allergic; 18 are open to participants now.
Browse Conjunctivitis, Allergic studies →6 of the 95 studies in Conjunctivitis, Allergic with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 8+
Dompé Farmaceutici S.p.A · Sites in United States, Argentina, Czechia and 11 more countries
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
Telios Pharma, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 12 Conjunctivitis, Allergic studies recruiting now, 8 (67%) set no upper age limit and 4 (33%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 29 · Phase 3 36 · Phase 4 20
First in 2000; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 87 across 174 interventional studies indexed under Conjunctivitis, Allergic.
Median enrollment 94 across the 90 interventional studies, 100 across the 5 observational. Of the 84 that completed or were terminated, 50 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 95 have an industry lead sponsor. The 10 most frequent:
Aldeyra Therapeutics, Inc. is the lead sponsor of 35 studies on the registry; 1 is open to participants now.
Of its 29 completed or terminated interventional studies of FDA-regulated products, 25 (86%) have results posted.
Aldeyra Therapeutics, Inc. has 7 studies filed under Conjunctivitis, Allergic — fewer than ten, so there is no comparison to draw.
1 of the studies in Conjunctivitis, Allergic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07938632Telios Pharma, Inc.TL-925 for the Treatment of Allergic Conjunctivitis | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies in Conjunctivitis, Allergic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
Drug: ADX-102 Ophthalmic Drops (0.5%)
ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
Drug: ADX-102 Ophthalmic Drops (0.1%)
Vehicle of ADX-102 Ophthalmic Drops
Drug: Vehicle of ADX-102 Ophthalmic Drops
ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.
Ocular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.
Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
Time frame: Efficacy assessment period (Day 1 through Day 15), Day 15 reported.
Ocular Itching Evaluated by the Subject at 15(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.
Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
Time frame: Efficacy assessment period (Day 1 through Day 15), Day 15 reported.
Ocular Itching Evaluated by the Subject at 20(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15.
Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
Time frame: Efficacy assessment period (Day 1 through Day 15), Day 15 reported.
| Milestone | ADX-102 Ophthalmic Drops (0.5%) | ADX-102 Ophthalmic Drops (0.1%) | Vehicle of ADX-102 Ophthalmic Drops |
|---|---|---|---|
| Started | 53 | 51 | 50 |
| Completed | 51 | 49 | 49 |
| Not completed | 2 | 2 | 1 |
Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
| units on a scale | ADX-102 (0.5%) | ADX-102 (0.1%) | Vehicle |
|---|---|---|---|
| Ocular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15. | 2.020 ± 0.9821 | 2.398 ± 0.8290 | 2.515 ± 0.9661 |
Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
| units on a scale | ADX-102 (0.5%) | ADX-102 (0.1%) | Vehicle |
|---|---|---|---|
| Ocular Itching Evaluated by the Subject at 15(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15. | 1.662 ± 1.0085 | 1.801 ± 0.9601 | 1.985 ± 0.9768 |
Ocular itching using the Ora Calibra® Conjunctival Allergen Challenge Ocular Itching Scale (0 = least, 4= most), where a higher score is indicative of a worse outcome. The intervention was administered bilaterally.
| units on a scale | ADX-102 (0.5%) | ADX-102 (0.1%) | Vehicle |
|---|---|---|---|
| Ocular Itching Evaluated by the Subject at 20(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15. | 1.152 ± 0.9799 | 1.434 ± 0.9773 | 1.551 ± 1.0433 |
Collected over Adverse event data was captured for approximately 5 weeks for each subject during clinical trial participation.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ADX-102 Ophthalmic Drops (0.5%) | 0/53 (0%) | 0/53 (0%) | 0/53 (0%) |
| ADX-102 Ophthalmic Drops (0.1%) | 0/51 (0%) | 0/51 (0%) | 0/51 (0%) |
| Vehicle of ADX-102 Ophthalmic Drops | 0/49 (0%) | 0/49 (0%) | 0/49 (0%) |
| Age, Categorical(Participants) | ADX-102 Ophthalmic Drops (0.5%) | ADX-102 Ophthalmic Drops (0.1%) | Vehicle of ADX-102 Ophthalmic Drops | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 51 | 47 | 48 | 146 |
| >=65 years | 2 | 4 | 2 | 8 |
| Sex: Female, Male(Participants) | ADX-102 Ophthalmic Drops (0.5%) | ADX-102 Ophthalmic Drops (0.1%) | Vehicle of ADX-102 Ophthalmic Drops | Total |
|---|---|---|---|---|
| Female | 40 | 27 | 30 | 97 |
| Male | 13 | 24 | 20 | 57 |
| Ethnicity (NIH/OMB)(Participants) | ADX-102 Ophthalmic Drops (0.5%) | ADX-102 Ophthalmic Drops (0.1%) | Vehicle of ADX-102 Ophthalmic Drops | Total |
|---|---|---|---|---|
| Hispanic or Latino | 4 | 5 | 3 | 12 |
| Not Hispanic or Latino | 49 | 46 | 46 | 141 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | ADX-102 Ophthalmic Drops (0.5%) | ADX-102 Ophthalmic Drops (0.1%) | Vehicle of ADX-102 Ophthalmic Drops | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 34 | 34 |
| Black or African American | 18 | 17 | 13 | 48 |
| White | 35 | 33 | 0 | 68 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 2 | 2 |
| Iris Color (Right Eye)(participants) | ADX-102 Ophthalmic Drops (0.5%) | ADX-102 Ophthalmic Drops (0.1%) | Vehicle of ADX-102 Ophthalmic Drops | Total |
|---|---|---|---|---|
| Black | 0 | 0 | 1 | 1 |
| Blue | 8 | 11 | 10 | 29 |
| Brown | 31 | 29 | 26 | 86 |
| Hazel | 6 | 5 | 7 | 18 |
| Green | 8 | 5 | 6 | 19 |
| Gray | 0 | 1 | 0 | 1 |
| Other | 0 | 0 | 0 | 0 |
| Iris Color (Left Eye)(participants) | ADX-102 Ophthalmic Drops (0.5%) | ADX-102 Ophthalmic Drops (0.1%) | Vehicle of ADX-102 Ophthalmic Drops | Total |
|---|---|---|---|---|
| Black | 0 | 0 | 1 | 1 |
| Blue | 8 | 11 | 10 | 29 |
| Brown | 31 | 29 | 26 | 86 |
| Hazel | 6 | 5 | 7 | 18 |
| Green | 8 | 5 | 6 | 19 |
| Gray | 0 | 1 | 0 | 1 |
| Other | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
The record gives a start of Dec 2016, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2023, 5 years 8 months after primary completion. A results delay was requested in Apr 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Reproxalap